Wednesday, March 05, 2025 | 04:15 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Covid: Molnupiravir sales may get hit amid safety concerns flagged by ICMR

Doctors say will prescribe if benefits outweigh risks; Clinicians also feel GoI should clarify its stand on Molnupiravir use

Covid treatment pill Molnupiravir (Photo: Reuters)
Premium

Covid treatment pill Molnupiravir (Photo: Reuters)

Sohini Das Mumbai
After the chief of India’s apex health research organisation said on Wednesday raised concerns around the safety of using oral antiviral drug molnupiravir, doctors felt that the government needs to clarify its stand. Also, industry sources said that prescription rates may go down among doctors after such safety concerns were raised.

Satyanarayana Mysore, HOD & Consultant-Pulmonology, Lung Transplant Physician and Karnataka Covid-19 task force member told Business Standard that it is strange that two arms of the government are not on the same page. He added that after the Drugs Controller General of India (DCGI) gave approval to a drug,

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in